Fred Hutchinson

SAN DIEGO — B-cell maturation antigen chimeric antigen receptor T cells that harbor a fully human single-chain variable fragment with a defined composition of CD4-positive and CD8-positive T cells appeared potent among patients with heavily pretreated, high-risk multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — The addition of a transplant-specific comorbidity score to risk stratification appeared to negate the survival benefit of hematopoietic stem cell transplantation among older patients with acute myeloid leukemia, according to results of a prospective, multicenter, longitudinal study presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A personalized risk prediction model developed using machine learning showed utility as a predictive and prognostic tool among patients with myelodysplastic syndrome, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Patients with large B-cell lymphoma who experienced progressive disease following anti-CD19 chimeric antigen receptor T-cell therapy had poor long-term outcomes, according to results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Consolidative hematopoietic stem cell transplant after CD19-directed chimeric antigen receptor T-cell therapy prolonged leukemia-free survival for certain pediatric and young adult patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, according to results of the PLAT-02 trial presented at ASH Annual Meeting and Exposition.

An experimental therapy demonstrated promising efficacy when evaluated in a small cohort of patients with advanced head and neck squamous cell carcinoma, according to results of an open-label dose escalation study.

The FDA approval of ibrutinib for adults with chronic graft-versus-host disease may herald a practice-changing breakthrough in the management of this posttransplant complication.

CHICAGO — Colorectal cancer treatment for patients who lived in western Washington State cost more than twice as much as treatment for individuals with the same malignancy who lived in a demographically similar region in Canada, according to study results presented at ASCO Annual Meeting.

The American Association for Cancer Research announced the newly elected fellows of the AACR Academy.

SALT LAKE CITY — Ruxolitinib treatment prior to allogeneic hematopoietic stem cell transplant appeared safe and aided in the prevention of cytokine release syndrome among patients with myelofibrosis, according to results of a phase 2 prospective study presented at the BMT Tandem Meetings.